EBC

ENG

INSEMA

SABCS 2024

To Omit or Not to Omit: Rethinking SNL Biopsy

R. Dent, A. Gennari, D. Lüftner, V. Guarneri, E. Senkus-Konefka, A. Schneeweiss

ENG

OlympiA, BRCA BCY Collaboration

SABCS 2024

More testing - more surgery?

M. Untch, N. Harbeck, E. De Azambuja, E. Senkus, S. Tolaney, S. Paluch-Shimon

ABC

ENG

DB-06, PADMA, EMBER-3

SABCS 2024

Practice changing combinations, treatment beyond…

E. Senkus, H.Rugo, N. Harbeck, M. Untch, R. Dent, V. Dieras

ENG

PATINA

SABCS 2024

Challenging the first line treatment and chemotherapy -…

S. Paluch-Shimon, A. Gennari, D. Lüftner, V. Guarneri, V. Diéras, A. Schneeweiss

The highlights of SABCS24 for HER2+ breast cancer

ENG

Fascinate, PATINA

SABCS 2024

CDK4/6i and ADC therapy for HER2+ and many more ADC…

N. Harbeck, W. Janni, B. Pistilli, P. Fasching, D. Lüftner, M. Untch

ENG

FASCINATE-N

SABCS 2024

FASCINATE-N – GS1-04

Gil Morgan, MD

ENG

PATINA

SABCS 2024

PATINA – GS2-12

Gil Morgan, MD

The highlights of SABCS24 for TNBC

ENG

GeparDouze, CamRelief, OlympiA

SABCS 2024

Ambivalent feelings about immunotherapy, but reassuring…

N. Harbeck, W. Janni, B. Pistilli, P. Fasching, H. Rugo, D. Lüftner

ENG

GeparDouze

SABCS 2024

GeparDouze – GS3-05

Gil Morgan, MD

ENG

CamRelief

SABCS 2024

CamRelief – GS3-06

Gil Morgan, MD

ENG

OlympiA

SABCS 2024

OlympiA GS1-09

Gil Morgan, MD

The highlights of SABCS24 for HR+ breast cancer

ENG

PADMA, RW OS CDK4/6i, EMBER-3, ADAPT

SABCS 2024

New data on CDK4/6i, oral SERDs and combinations, and…

N. Harbeck, W. Janni, B. Pistilli, P. Fasching, H. Rugo, D. Lüftner

ENG

RW OS CDK4/6i

SABCS 2024

RW OS CDK4/6i – PS2-03

Gil Morgan, MD

ENG

EMBER-3

SABCS 2024

EMBER-3 – GS1-01

Gil Morgan, MD

ENG

ADAPT

SABCS 2024

ADAPT – GS3-04

Gil Morgan, MD

eBC - 100 seconds

ENG

OlympiA

SABCS 2024

Exciting updates on OlympiA

Shani Paluch-Shimon, MD

ENG

SUPREMO

SABCS 2024

Time to limit postmastectomy radiotherapy indications

Elzbieta Senkus-Konefka, MD, PhD

ENG

OlympiA

SABCS 2024

Olaparib after (neo)adjuvant chemotherapy

Evandro de Azambuja, MD, PhD

ENG

EMBER-3, GBG-96-GeparDouze, Destiny-Breast06

SABCS 2024

My highlights of SABCS 2024

Giuseppe Curigliano, MD, PhD

ENG

TAILORx

SABCS 2024

Who need anthracyclines for node-negative HR+ BC

Hope Rugo, MD

ENG

INSEMA

SABCS 2024

No axillary surgery necessary in selected patients

Diana Lüftner, MD

ENG

BRCA BCY Collaboration

SABCS 2024

Survival benefit for patients with risk-reducing…

Shani Paluch-Shimon, MD

ENG

BRCA BCY Collaboration

SABCS 2024

Risk reducing mastectomy in patients with BRCA mutation

Michael Untch, MD

ENG

ZEST

SABCS 2024

ctDNA in follow-up - not for everyday clinical…

Andreas Schneeweiss, MD

ENG

INSEMA

SABCS 2024

The beginning of the end of sentinel lymph nodes

Wolfgang Janni, MD

ENG

BRCA BCY Collaboration, OlympiA

SABCS 2024

BRCA-mut population - impact of surgery & OlympiA -…

Véronique Diéras, MD

ENG

SABCS 2024

Older EBC patients should also undergo surgery

Andreas Schneeweiss, MD

ENG

ZEST

SABCS 2024

From the ZEST study to the german SURVIVE study

Wolfgang Janni, MD

HR+

ENG

SOLTI VALENTINE

SABCS 2024

Phase 2 neoadjuvant study with HER3 DXd

Barbara Pistilli, MD

ENG

OlympiA

SABCS 2024

Targets are important in EBC

Alessandra Gennari, MD, PhD

ENG

TAILORx

SBCS 2024

Fine-tuning of chemotherapy in node-negative luminal…

Elzbieta Senkus-Konefka, MD, PhD

ENG

WSG ADAPT

SABCS 2024

Who needs chemotherapy?

Nadia Harbeck, MD, PhD

HER2+

ENG

MARGOT

SABCS 2024

Is Margetuximab better than trastuzumab?

Sara M. Tolaney, MD

ENG

TRAIN-3

SABCS 2024

Neo-adjuvant monitoring with MRT & US can reduce…

Andreas Schneeweiss, MD

ENG

FASCINATE-N

SABCS 2024

Fascinating data from Shanghai

Wolfgang Janni, MD

ENG

TOUCH

SABCS 2024

Equivalence to chemotherapy with the combination of…

Eva M. Ciruelos, MD, PhD

TNBC

ENG

GeparDouze

SABCS 2024

Atezolizumab does not improve EFS in TNBC

Andreas Schneeweiss, MD

ENG

KEYNOTE-522

SABCS 2024

KEYNOTE-522 Interim analysis 4: Biomarkers

Peter A. Fasching, MD

ENG

A-Brave

SABCS 2024

Biomarker analysis from the A-Brave trial

Valentina Guarneri, MD, PhD

Multilanguage

ITA

A-Brave

SABCS 2024

Analisi dei biomarcatori nello studio A-Brave

Valentina Guarneri, MD, PhD

POL

TAILORx

SABCS 2024

Jaka chemioterapia u chorych na raki ER+/HER2- bez…

Elzbieta Senkus-Konefka, MD, PhD

FRA

SOLTI VALENTINE

SABCS 2024

Étude de phase 2 néoadjuvante avec HER3 DXd

Barbara Pistilli, MD

FRA

BRCA BCY Collaboration, OlympiA

SABCS 2024

Population BRCA-mut - impact de la chirurgie & OlympiA…

Véronique Diéras, MD

ITA

OlympiA

SABCS 2024

I bersagli sono importanti nella EBC

Alessandra Gennari, MD, PhD

ESP

TOUCH

SABCS 2024

Equivalencia a la quimioterapia con la combinación de…

Eva M. Ciruelos, MD, PhD

ITA

SOLTI VALENTINE

SABCS 2024

Studio neoadiuvante di fase 2 con HER3 DXd

Barbara Pistilli, MD

POR

OlympiA

SABCS 2024

OlympiA

Evandro de Azambuja, MD, PhD

ITA

EMBER-3, GBG-96-GeparDouze, Destiny-Breast06

SABCS 2024

I miei punti di forza di SABCS 2024

Giuseppe Curigliano, MD, PhD

POL

SUPREMO

SABCS 2024

Czas na ograniczenie wskazań do radioterapii po…

Elzbieta Senkus-Konefka, MD, PhD

aBC - 100 seconds

ENG

PRO B

SABCS 2024

Improving patient management in metastatic BC trough…

Volkmar Müller, MD

ENG

DESTINY-Breast06

SABCS 2024

HER2-targeted therapy: quality of life in focus

Volkmar Müller, MD

HR+

ENG

EMBER-3, PATINA

SABCS 2024

New SERD in phase-3-trial & CDK4/6 inhibitor in HR+ MBC

Véronique Diéras, MD

ENG

SABCS 2024

CDK4/6i more equal than not

Hope Rugo, MD

ENG

EMBER-3

SABCS 2024

Abstract Nr. 1: Imlunestrant

Diana Lüftner, MD

ENG

EMBER-3

SABCS 2024

Efficacy data of EMBER-3

Valentina Guarneri, MD, PhD

ENG

SABCS 2024

Comparison of all CDK4/6 in combination with AI in the…

Peter A. Fasching, MD

ENG

PADMA

SABCS 2024

CDK4/6 inhibitor + ET is the best start for HR+…

Shani Paluch-Shimon, MD

ENG

EMBER-3

SABCS 2024

EMBER-3

Peter A. Fasching, MD

ENG

PADMA

SABCS 2024

Targeting endocrine pathways is superior to Chemo in…

Alessandra Gennari, MD, PhD

HER2+

ENG

CLEOPATRA

SABCS 2024

HER2DX might optimize 1st line in HER2+ mBC

Javier Cortés, MD, PhD

ENG

PATINA

SABCS 2024

Practice changing results for ER+/HER2+ patients

Sara M. Tolaney, MD

ENG

DEMETHER

SABCS 2024

Optimizing 1st line treatment with T-DXd followed HP in…

Javier Cortés, MD, PhD

ENG

PATINA

SABCS 2024

Significant and clinical relevant benefit of the…

Eva M. Ciruelos, MD, PhD

ENG

DETECT V

SABCS 2024

CDK4/6 + HER2-targeted therapy without chemo for triple…

Volkmar Müller, MD

ENG

DESTINY-Breast12

SABCS 2024

Endocrine combination therapy for triple positive BC

Volkmar Müller, MD

ENG

PATINA

SABCS 2024

CDK4/6 inhibitors effective also in luminal HER2+…

Elzbieta Senkus-Konefka, MD, PhD

ENG

PATINA

SABCS 2024

CDK4/6 inhibitor in HER2+ metastatic BC

Diana Lüftner, MD

ENG

DESTINY-Breast12

SABCS 2024

DESTINY-Breast 12: Quality of life

Nadia Harbeck, MD, PhD

Multilanguage

ITA

PADMA

SABCS 2024

Il targeting delle vie endocrine è superiore alla CT…

Alessandra Gennari, MD, PhD

ESP

DEMETHER

SABCS 2024

Optimización del tratamiento de 1ª línea con T-DXd…

Javier Cortés, MD, PhD

ITA

EMBER-3

SABCS 2024

Dati di efficacia di EMBER-3

Valentina Guarneri, MD, PhD

POL

PATINA

SABCS 2024

Inhibitory CDK4/6 skuteczne również w rakach…

Elzbieta Senkus-Konefka, MD, PhD

ESP

CLEOPATRA

SABCS 2024

HER2DX podría optimizar la 1ª línea en el CMM HER2+.

Javier Cortés, MD, PhD

ESP

PATINA

SABCS 2024

Beneficio significativo y clínicamente relevante de la…

Eva M. Ciruelos, MD, PhD

FRA

EMBER-3, PATINA

SABCS 2024

Nouveau SERD en phase 3 d'essai & Inhibiteur CDK4/6…

Véronique Diéras, MD